The era of molecular taxonomy of neoplasms – Neoplasms of the urinary tract
Urothelial carcinoma of the bladder is a common malignancy causing an estimated 150,000 deaths per year. Treatment for muscle-invasive bladder cancer has not advanced beyond cisplatin-based combination chemotherapy and surgery in the past 30 years and no new drugs for the disease have been approved during that time. In contrast to other malignancies, molecular diagnostics are not established yet for routine clinical management for patients with urothelial cancer of the bladder. Studies have identified gene expression patterns that classify tumors into clinically relevant molecular subtypes. Molecular subtypes were defined by distinct gene expression signatures which are specific for cell cycle, cytokeratins, cell adhesion, receptor tyrosine kinases and immune response. These distinct molecular profiles may help define subsets of patients who are expected to respond positively to chemotherapy and to molecularly targeted therapy. In the current review, two molecular taxonomies of bladder cancer are investigated.
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).